Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database

OBJECTIVES: Although several years have passed since biologic disease modifying antirheumatic drugs were introduced to the market, considerable disparities in access still remain. Tumour necrosis factor inhibitors (TNFi) have proven to be highly effective and safe for treating patients with rheumati...

Descripción completa

Detalles Bibliográficos
Autores principales: Stajszczyk, Marcin, Obarska, Izabela, Jeka, Slawomir, Batko, Bogdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423465/
https://www.ncbi.nlm.nih.gov/pubmed/37328194
http://dx.doi.org/10.1136/ard-2022-223696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423465/
https://www.ncbi.nlm.nih.gov/pubmed/37328194
http://dx.doi.org/10.1136/ard-2022-223696

Ejemplares similares